1. Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK.
- Author
-
Ceesay, M. Mansour, Sadique, Zia, Harris, Ross, Ehrlich, Alice, Adams, Elisabeth J., and Pagliuca, Antonio
- Subjects
- *
COMMUNICABLE disease treatment , *MYCOSES , *DIAGNOSTIC services , *MEDICAL care costs , *ANTIFUNGAL agents , *LENGTH of stay in hospitals , *DRUG utilization - Abstract
Objectives: The direct cost of invasive fungal disease (IFD) includes antifungal drugs as well as diagnostic tests. The aim of this study was to determine these costs. Methods: A total of 203 haematology patients were enrolled into the study and followed for a median of 556 days. Data were prospectively collected on antifungal drugs, diagnostic tests, length of stay and antibiotic usage. Results: The overall mean (IQR) cost of care per patient (using UK-based reference costs) was £88911 (45339-121594), £61509 (39748-78383), £50332 (23037-72057) and £34075 (19928-43900) for proven/probable IFD, possible IFD, not classified and no evidence of IFD, respectively (P<0.001). The attributable cost of IFD was £54836. Inpatient hospital stay accounted for nearly 74% of costs. In proven/probable IFD inpatient care, antifungals, antibiotics and IFD status accounted for 68%, 25%, 5% and 2%, respectively, compared with 85%, 11%, 2% and 2%, respectively, for no IFD (P<0.001). Among the allogeneic transplant patients, £36914 (60%) of the total cost (£60917) was used during the first 100 days. Conclusions: IFD was associated with longer length of stay and higher total overall cost of care, with attributable costs greater than £50000 per case of IFD. Costs for inpatient stay far outstrip the cost of antifungal agents. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF